Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

NEW YORK, June 24 /PRNewswire/ — Underscoring its commitment to scientific advancement, Pfizer Inc will launch Think Science Now, a science awareness program to promote exceptional researchers who ...

Pharmaceutical companies are keen to have a stake in the personalized medicine market, viewed as a growing trend in the future of healthcare and a significant source of life science innovation. As ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The Pfizer flu vaccine uses the same type of messenger RNA science that was used in the ...

Pfizer Inc. (NYSE: PFE) CEO Albert Bourla sharply criticized Robert F. Kennedy's views on vaccines, calling them "anti-science." He suggested that meaningful progress on immunization policy would ...